|

Azacitidine or decitabine Clinical Trials

1 actively recruiting trial

Also known as: Hypomethylating Agent

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1

Indications

  • Venetoclax1
  • Hypomethylating Agent1
  • Myeloid Malignancy1
  • Cancer1

Other1 trial

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.